Provention Bio to Present at the Jefferies Virtual Healthcare Conference

Rhea-AI Summary

Provention Bio, Inc. (Nasdaq: PRVB) announces its participation in the Jefferies Virtual Healthcare Conference on June 3, 2021, at 10:30 AM E.T.. The session will be available via live webcast on the company's website, with an archive accessible for 30 days post-event. Provention Bio focuses on developing therapies for immune-mediated diseases, notably their lead candidate teplizumab, which aims to delay type 1 diabetes in at-risk individuals. More details can be found on their website.

RED BANK, N.J., June 1, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced management will present at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 10:30 AM E.T.

The presentation will be webcast live and can be accessed by visiting the Events and Webcasts section of the Company's website: http://investors.proventionbio.com/events. The webcast will be archived on the Company's website for 30 days following the presentation.

About Provention Bio, Inc.:

Provention Bio, Inc. (Nasdaq: PRVB) is a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated disease. The BLA for teplizumab, its lead investigational drug candidate, for the delay of clinical type 1 diabetes in at-risk individuals, has been filed by the FDA. The Company's pipeline includes additional clinical-stage product candidates that have demonstrated in pre-clinical or clinical studies proof-of-mechanism and/or proof-of-concept in other autoimmune diseases, including celiac disease and lupus. Visit www.ProventionBio.com for more information and follow us on Twitter: @ProventionBio.

Internet Posting of Information:

Provention Bio, Inc. uses its website, www.proventionbio.com, as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation F.D. Such disclosures will be included on the Company's website in the "News" section. Accordingly, investors should monitor this portion of the Company's website, in addition to following its press releases, SEC filings and public conference calls and webcasts.

Investor Contacts:

Robert Doody, VP of Investor Relations
rdoody@proventionbio.com
484-639-7235

Sam Martin, Argot Partners
proventionbio@argotpartners.com   
212-600-1902

Media Contact:
Lori Rosen, LDR Communications
lori@ldrcommunications.com
917-553-6808

View original content to download multimedia:http://www.prnewswire.com/news-releases/provention-bio-to-present-at-the-jefferies-virtual-healthcare-conference-301302476.html

SOURCE Provention Bio, Inc.

FAQ

When will Provention Bio present at the Jefferies Virtual Healthcare Conference?

Provention Bio will present on June 3, 2021, at 10:30 AM E.T.

How can I access the Provention Bio conference presentation?

The presentation will be webcast live on Provention Bio's website and archived for 30 days.

What is Provention Bio's main focus in biopharmaceuticals?

Provention Bio focuses on therapies that intercept and prevent immune-mediated diseases.

What is teplizumab and its significance to Provention Bio?

Teplizumab is Provention Bio's lead investigational drug aimed at delaying clinical type 1 diabetes in at-risk individuals.

Where can I find more information about Provention Bio?

Visit Provention Bio's website at www.ProventionBio.com for more information.